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Background: Moral philosophers have debated the extent to which persons are individually responsible for the
onset of and recovery from addiction. Empirical investigators have begun to explore counselors’ attitudes on these
questions. Meanwhile, a separate literature has investigated counselors’ negative attitudes towards naltrexone, an
important element of medication-assisted treatment for alcohol addiction. The present study bridges the literature
on counselor views about responsibility for addiction with the literature on attitudes towards naltrexone. It
investigates the extent to which a counselor’s views of individual responsibility for alcohol addiction are
related to that counselor’s views of naltrexone.
Methods: Using a vignette-based survey of 117 addiction treatment professionals, the study analyzes the relationship
between an addiction counselor’s views about individual responsibility for alcohol addiction and using naltrexone to
treat it.
Results: We find a significant difference in counselors who assign greater responsibility to a person for the onset of
alcohol addiction. They agreed more strongly with several objections to naltrexone, including worries about
compliance, naltrexone’s side effects outweighing its benefits, naltrexone treating symptoms but not underlying
causes, and the idea that medication may undermine a person’s motivation to recover. Combined views of greater
responsibility for addiction’s onset and recovery also significantly predicted stronger agreement with objections.
Conclusions: We conclude that there is a strong relationship between a counselor assigning higher individual
responsibility for addiction and holding more negative views about naltrexone. The study also sheds light on one
reason why the model of addiction as a brain disease has had limited impact on clinical practice.
Keywords: Ethics, Alcohol addiction, Clinical practice patterns, Evidence-based medicineBackground
Moral philosophers and addiction treatment profes-
sionals have explored the relationship between addiction
and individual responsibility. Foddy and Savulescu [1]
argue that conceptual models tend to characterize addic-
tion in one of two ways: either as a symptom of a disease
or as a failure of self-control. On the first account—the
disease model of addiction—drug or alcohol use hijacks
normal processes of motivation in the brain. Persons who
continue to use drugs do so because biological changes
limit their capacity to make rational choices. They may be
individually responsible for their decision to initially use
a substance, but after sufficient use, changes to their* Correspondence: raj2@princeton.edu
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unless otherwise stated.biological makeup make them no longer responsible for
recovery. In contrast, the second account of addiction—
the failure of self-control model—paints “addicts” as
weak-willed persons who are locked in a battle for power
over their pleasure-seeking impulses. In this model of ad-
diction, persons are both individually responsible for their
decision to use a substance and individually responsible
for their recovery or failure to do so.
Recently, empirical researchers have begun to investi-
gate the beliefs about responsibility that trained addiction
counselors hold [2-5]. Studying U.S. addiction counselors,
Kloss and Lisman [2] found that most counselors assigned
low degrees of responsibility to persons for both the onset
of and recovery from their alcohol addiction. Later studies
of U.S. addiction counselors have investigated contribu-
tors to these attitudes. Counselors with higher rates ofl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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personally recovering from addiction hold a person sig-
nificantly less responsible for addiction’s onset [4,5].
In contrast, counselors who identify cognitive behavioral
therapy (CBT) as their theoretical orientation hold a per-
son significantly more responsible for addiction’s onset,
a finding the authors link to the responsibility-focused
orientation of CBT [4]. Meanwhile, the only factor identi-
fied in the literature that significantly predicted assign-
ments of responsibility for recovery from addiction is a
counselor’s neuroscience exposure, with more exposure
associated with assigning significantly more responsibility
[4]. While these studies analyzed attitudes from U.S.-based
addiction counselors, Palm’s study of a Swedish sample of
addiction counselors found that counselors aligned with
their U.S. counterparts in believing that persons are not
highly responsible for the onset of their addiction. Yet the
counselors diverged from their U.S. counterparts in believ-
ing that persons are highly responsible for recovery [3].
This literature has characterized counselor beliefs about
responsibility for alcohol and other addictions, as well as
characteristics of a counselor associated with those beliefs.
Meanwhile, a separate literature has focused on the
“implementation gap” in alcohol addiction treatment
where centers fail to adhere to evidence-based treatment
[6]. One way that centers deviate from evidence-based
treatment is in their low uptake of naltrexone (Revia
or Depade), a selective opioid antagonist that has been
shown to be both safe and effective in decreasing the
frequency and severity of relapse for persons with al-
cohol addiction [7,8]. Naltrexone in combination with
psychosocial treatment is recommended as a first-line
treatment for the condition [9]. Yet despite the scientific
support for naltrexone, and despite its approval for alco-
hol addiction since 1995, prescriptions for naltrexone are
low at both the level of treatment centers and individual
counselors. The percentage of treatment facilities report-
ing any use of naltrexone has declined significantly since
the drug was approved, declining from 49.2% in 1995 to
41.7% in 2004 [10]. Even among treatment programs that
use naltrexone, only 3-9% of alcohol dependent clients re-
ceived a prescription [10,11]. While it is true that naltrex-
one has small to medium effect sizes [12] and these are
lower than some counselors would like [7], fewer than 1
in 10 clients receive a naltrexone prescription. Though
not every client with alcohol addiction should receive a
prescription, naltrexone still appears under-utilized rela-
tive to its effectiveness.
Research on reasons for this low utilization has identi-
fied several contributors. The primary reasons for a coun-
selor’s reluctance to recommend naltrexone is inadequate
knowledge of the medication and perceiving naltrexone to
be high in cost [13]. Perceptions of adverse effects, worries
that the local Alcoholics Anonymous chapter is opposedto medication, and a counselor’s geographic location
(e.g. Tennessee) were also associated with greater re-
luctance to prescribe [13]. More recent research has con-
firmed that a counselor’s type of training plays a large role
in support for naltrexone prescription—with psychiatrists
and other physicians significantly more likely to support
naltrexone and other medications than persons without
medical degrees [14]. In the US, non MD counselors
do not have the ability to prescribe and their clients
may have limited access to a psychiatrist to prescribe
naltrexone. Other recent research has illustrated that al-
though counselors may perceive naltrexone as high in cost,
this perception fails to align with the reality of naltrexone
coverage, since most insurance plans make naltrexone af-
fordable [15].
This research on low utilization of naltrexone has un-
covered important contributors to low uptake. However,
no published studies of which we are aware have bridged
this literature on contributors to low naltrexone uptake
with the literature on counselors’ views of individual re-
sponsibility for alcohol addiction. The present paper be-
gins to bridge this gap. We focus on whether there is a
relationship between a counselor’s views of individual re-
sponsibility for alcohol addiction and that counselor’s
negative attitudes towards the use of naltrexone to treat
the condition. While these negative attitudes are not the
only factor influencing low uptake of medication, they
may be one important barrier.
Methods
Recruitment methods
Participants were recruited through Qualtrics, a research
software firm that provides access to panelists who
agreed to be contacted to participate in relevant surveys.
We used Qualtrics because in-person recruiting from a
single addiction treatment facility or recruiting from a
single geographic area (e.g. the New York metropolitan
area) would likely result in a sample with a more narrow
set of ideological views about addiction and clientele
profile than recruiting from a national sample where the
majority of states, insurance types, counselor educational
backgrounds, and experience levels are represented. In
addition, using a snowball sampling method, whereby
we recruit personal contacts in the addiction treatment
field and then these respondents refer others for recruit-
ment, would likely also result in a significantly less di-
verse sample than those recruited from a national pool.
Qualtrics attempted to gear this survey towards panel-
ists who indicated that they had experience treating per-
sons with substance addictions. Following the University
of Pennsylvania IRB decision that the study was exempt
from full review, panelists were sent an email invitation to
participate in a survey. Qualtrics sends out emails to per-
sons who have registered to participate in survey research.
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this specific survey, Qualtrics sent emails to members of
that pool who, on their profiles, had indicated experience
treating alcohol addiction. Because we wanted to ensure
that our sample was limited to trained addiction coun-
selors, our survey included further screening questions.
The consent form specified that the survey was intended
for a “trained addiction counselor who works with per-
sons with various substance abuse addictions” (emphasis
added). Participants were then asked to respond to the
question “Do you currently or have you in the past treated
persons with substance addictions?” and were screened
out if they answered “no”. In line with payment levels
for survey participants with particular professional ex-
periences, respondents who completed the survey re-
ceived $15 in payment. Participants completed the study
in October 2012.
Sample characteristics
Of the 382 potential participants who consented and
responded to the screening question about whether they
are treating or have treated persons with addiction, 255
persons (67%) responded “No” and were screened out of
the survey while the remaining 127 persons (33%) an-
swered “Yes” and were allowed to proceed. The final
sample contained 117 participants who answered all the
questions in the survey. Table 1 provides a summary of
the sample. The mean age was 35 (SD = 11.32) and mean
number of years working with persons with substance
abuse was 2.5 (SD = 1.15). The insurance makeup of the
clients treated by the counselor varied widely, butTable 1 Demographic characteristics of survey respondents









Highest level of schooling
Ph.D. in clinical psychology 8 (7%)
Ed.D. (doctorate in education) 2 (2%)
M.D. 5 (4%)
Master of Social Work or Master of Education 16 (13%)
B.A. or B.S. 41 (35%)
High school or G.E.D. 31 (26%)
Other (included counseling certification, other
Ph.D. or military substance abuse training)
14 (12%)displayed a mean of 45.1% publicly insured clients (SD =
28.49), 42.6% privately insured clients (SD = 27.10), and
a mean of 31.1% of clients paying out of pocket (SD =
30.21). Our sample’s composition of 48% BA/BS and
MA-level counselors is acceptable for two reasons. First,
PhD and MD-level professionals occupy a small minority
of the addiction treatment workforce: fewer than 60%
of addiction treatment programs even have a part-time
physician on staff [16] and the highest degree for over
60% of persons who identify themselves as addiction
counselors is a bachelor’s or master’s [17,18]. Second,
since non-MD counselors are the most prevalent on ad-
diction treatment staff, they can play multiple roles in
medication-assisted treatment. First, counselors can refer
clients to outside physicians with prescribing power. Sec-
ond, although the primary reason that few centers have a
physician on staff is inadequate insurance reimbursement
for addiction, counselor attitudes towards the importance
of medication might influence their willingness to advo-
cate for physician hiring. Finally, we expected trained
counselors to be aware of a medication that has been
FDA approved for alcohol addiction since 1995 [19].
Therefore, we included counselors who are not physi-
cians. A power analysis using G*Power suggested that
for a regression with thirteen predictor variables, and
that seeks a medium effect size difference in the dependent
variable (Cohen’s f2 = 0.3), the study is 95% powered at
100 participants [20]. Therefore, the present study, with
117 participants, was adequately powered to detect differ-
ences in the variable of interest (strength of agreement
with an objection to the use of naltrexone).
Addiction vignette
First, participants read a vignette describing a client with
alcohol addiction. The purpose of the vignette was to en-
sure that respondents had a relatively uniform “fictitious
client” in mind when rating objections to the use of medi-
cation for that client.
The first paragraph of the vignette, which describes
the symptoms of the person with alcohol addiction, was
taken from Kloss and Lisman’s [2] study of addiction
counselor attitudes towards the responsibility of a per-
son with alcohol addiction depicted in a vignette. The
original developers of the vignette constructed the symp-
toms based on the DSM-III-R depiction of psychoactive
substance dependence (alcohol). In our adaptation of the
vignette, we added three additional lines to describe the
clinician’s choice of treatment (naltrexone and a 12-step
program) and how another clinician at the treatment
center raises objections to naltrexone’s use.
The vignette presents two counselors with conflicting
viewpoints: one counselor who recommends naltrexone
and a 12-step program for the client, Paul; another
counselor who objects to the medication aspect of the
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mending both naltrexone and a 12-step program is that
most guidelines recommend combining naltrexone with
some other form of counseling or support [21], and 12-step
programs such as Alcoholics Anonymous have emphasized
that they are not opposed to the use of medication [22].
We had three reasons for using the second clinician’s
objections to the use of naltrexone as a starting point for
investigating counselor attitudes. First was to contextualize
the objections with reference to naltrexone’s use for
the specific client in the vignette. Second was to present
both positions on naltrexone (agreement with its use as
in the first counselor; disagreement with its use as in
the second counselor) as acceptable responses. Third
was that asking participants about agreement with an-
other counselor’s views minimized desirability biases
if participants were aware that the study’s purpose
was to examine the relationship between their view of
responsibility for addiction and their objections to
naltrexone.
In addition, the vignette was deliberately silent on cer-
tain details that might bias a counselor’s rating of the per-
son’s degree of responsibility for the onset of/recovery
from his addiction. It was also silent on details that could
influence the counselor’s agreement with various objec-
tions to the use of naltrexone. For example, the vignette
does not indicate how and why Paul started drinking.
It does not analyze the extent to which he might be
responsible for that decision. Finally, the vignette does
not indicate whether or not Paul takes opioids for which
naltrexone can cause withdrawal symptoms. In sum, the
vignette is composed of a neutral presentation of symp-
toms that should not influence the respondents’ 1) views
of addiction responsibility, or 2) attitudes towards naltrex-
one. Before fielding the vignette to respondents, we
piloted it for face validity with persons trained in treating
alcohol addiction:
Paul goes to an addiction treatment center due to his
inability to stop drinking without suffering withdrawal
symptoms. He is having difficulty going to work and
problems at home. He reports that at times, it is
difficult for him to get out of bed in the morning. He
reports having to drink twice as much as he used to
just to feel "normal".After a thorough evaluation, Paul is diagnosed with
Psychoactive Substance Dependence (Alcohol). Paul’s
clinician decides to treat him with Naltrexone
(ReVia), a drug that claims to reduce or eliminate
the rewarding effects of alcohol. He also recommends a
12-step program to Paul to attend. Another clinician
at the clinic raises various objections to the use of
Naltrexone for Paul’s treatment.Attitudes toward the use of medication
After reading the vignette, participants were asked to
rate the extent of their agreement on a 5-point Likert type
scale (1 = strongly disagree to 5 = strongly agree) with six
objections to the use of naltrexone to treat addiction
raised by a “dissenting clinician” at the clinic. We focused
on objections since the present study’s aim was to analyze
views of responsibility for addiction that lead to more
negative evaluations of naltrexone, which future work
should supplement with attention to both negative and
positive attitudes.
We surveyed the literature concerning counselor re-
luctance about naltrexone or other anti-addiction medi-
cations to develop the objections:
1. Paul will be unlikely to comply with taking the
medication.
2. The medication’s side effects (which include nausea,
headache, dizziness, anxiety and a small risk of
withdrawal symptoms) are not worth its benefits.
3. There’s a risk that Paul will use opioids that interfere
with the medication and cause serious side effects.
4. Naltrexone will treat the symptoms of Paul’s
alcoholism, but it will not improve the underlying
causes of his alcohol abuse.
5. Overcoming alcoholism without the use of medication
will strengthen Paul’s resolve and willpower.
6. The medication will diminish Paul’s motivation to
help himself and participate in the 12-step program.
Objection 1 stems from the fact that the most frequent
physician-reported barrier to naltrexone prescription is
worries about compliance [23]. Objection 2 originates in
the finding that although physician focus groups do not
perceive naltrexone’s side effects as a major barrier to its
use, clients rank naltrexone’s side effect profile as one of
the primary reasons why it is not more widely used [24].
Objection 3 is developed from the fact that naltrexone is
contraindicated for clients currently dependent on opi-
oids because of the severe withdrawal symptoms that
may occur [25]. Objection 4 stems from views that trace
the underlying causes of alcohol abuse to factors such as
a lack of attractive opportunities available to persons
with addiction or untreated psychiatric co-morbidities
[26]; naltrexone, as a medication that targets pleasure
derived from alcohol, does not address these perceived
causes. Objection 5 stems from the fact that some coun-
selors are reluctant to prescribe naltrexone to clients who
seem unwilling to commit themselves to the “hard work”
of treatment, a reluctance that appears rooted in the idea
that a client can better strengthen his or her willpower
through non-pharmacological treatment [23]. Objection 6
stems from a Family Physician Practice newsletter discus-
sion of potential reasons behind reluctance to prescribe
Johnson et al. Substance Abuse Treatment, Prevention, and Policy  (2015) 10:10 Page 5 of 13naltrexone. In the newsletter, a Harvard Medical School
physician describes “a sense among many counselors that
medications might diminish patients’ motivation to help
themselves or to participate in 12-step program activities”
[27]. These objections, drawn from existing research on
negative attitudes towards naltrexone, vary in their degree
of validity. For instance, rates of compliance for naltrex-
one range from 40% to 90%, making the objection some-
what valid depending on the rates with which the
counselor is familiar. In contrast, most conclude that the
side effects for naltrexone are generally mild and tolerable
[12], making the objection largely invalid. What was im-
portant for the present study was not counselors’ absolute
degree of agreement with each objection. Instead, the
present study focuses on whether counselor views about
responsibility significantly contributed to the variation in
the counselors’ degree of agreement with each objection.
Ratings of responsibility for the onset of and recovery
from addiction
We assessed perceptions of a client’s responsibility for
the onset of and recovery from addiction using a four-
item scale adapted from Kloss and Lissman [2]. The items
assessing views about responsibility for onset were:
1. Persons with alcoholism are responsible for the
onset of their dependency.
2. Persons with alcoholism could have avoided their
dependence.
The items assessing views about responsibility for re-
covery were:
1. Persons with alcoholism are personally responsible
for their recovery.
2. Persons with alcoholism are personally responsible
for creating a solution.
Respondents rated their extent of agreement on a 5-
point Likert type scale (1 = strongly disagree to 5 = strongly
agree). Responses to the two items about responsibility for
onset displayed a significant bivariate correlation using a
Pearson’s product–moment test (r = 0.48, n = 117, p <
0.001), so we combined the two items into a single re-
sponsibility for onset item that represented the average
of each participant’s two responses. Responses to the
items about responsibility for recovery also displayed a
significant bivariate correlation using a Pearson’s product–
moment test (r = 0.45, n = 117, p < 0.001), so the two items
were combined and averaged into a single item. These
items were used in model 2 and model 3 of our re-
gressions respectively. In addition, a counselor’s com-
bined view about addiction’s onset and his combined
view about addiction’s recovery displayed a significantbivariate correlation using Pearson’s (r = 0.33, n = 117,
p < 0.001). As a result, we created a combined “general
views about responsibility” item that represented the aver-
age of these two responses and analyzed the item in model
4 of our regressions.
Statistical analysis plan
We intended to treat each objection to naltrexone as a
distinct dependent variable in our analyses. However, to
test for any underlying factors for the six objections, we
performed a principal components analysis using varimax
rotation to see if any of the objections clustered together
in a meaningful way. The analysis yielded 2 factors, but
the factors only accounted for a combined total of 53.8%
of the variance. Furthermore, five out of the six objections
loaded onto one factor, with loading scores ranging from
0.43 (overcoming alcohol addiction will strengthen re-
solve) to 0.78 (the medication will diminish Paul’s mo-
tivation; the medication’s side effects are not worth its
benefits). The second factor only included one item
(medication will not improve the underlying cause of
alcohol abuse). Therefore, we decided that the factors
were not a useful means of clustering the objections to
serve as dependent variables.
While the factor analysis revealed the objections did
not meaningfully disaggregate into multiple scales, the
Cronbach’s Alpha score for all of the objections was 0.63,
with the objection about medication failing to treat addic-
tion’s underlying cause the least similar to other objec-
tions. With that item removed, the scale’s Cronbach’s
Alpha would have risen to 0.66. Since this still falls below
the accepted Cronbach’s Alpha cutoff for scales of 0.70
[28], we decided to examine each objection to addiction
medication as a separate dependent variable in separate
regressions rather than combining them into a single
scale. To account for the fact that we were perform-
ing multiple regressions (one set for each of the objec-
tions), we performed Bonferroni correction, resulting in a
new cutoff of p < 0.008 for significance.
After examining distributional characteristics of the study
factors, we used STATA version 13.1 (College Station, TX)
to perform multiple regression analyses to examine the
predictive effect of responsibility ratings on each objection
to addiction medication. Each objection served as distinct
continuous dependent variable that measured a coun-
selor’s degree of agreement with the objection.
The predictor variables were the following demographic
variables: gender (0 = female; 1 =male), age, type of school-
ing recoded into five distinct dummy variables (PhD; MD;
Master’s; Bachelor’s; other education), with high school
education-level as the reference category, years working
with persons with substance abuse, percent of clients who
are privately insured, percent of clients who are publicly
insured, percent of clients who pay out of pocket, and
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For brevity, we call these the counselor-characteristics
predictor variables. Model 1 examined these counselor-
characteristic variables. Model 2 combined these counselor-
characteristic variables with the counselor’s views about
responsibility for the onset of addiction. Model 3 com-
bined them with the counselor’s views about responsibility
for recovery from the addiction. Model 4 combined these
counselor-characteristic variables with a variable measur-
ing a counselor’s combined view of responsibility for the
onset of addiction and responsibility for recovery from
addiction.
Results
Descriptive data on ratings of responsibility
Counselors rated the person depicted in the vignette as
less responsible for the onset of his alcohol addiction
(M= 3.33, SD = 0.95) than for recovery from his alcohol ad-
diction (M= 3.81, SD = 0.84). A one-sample t-test showed
that this difference in means was significant, t(116) = 5.102,
p < 0.001. Table 2 presents the breakdown of views of re-
sponsibility. The combined item measuring beliefs about
responsibility for onset and beliefs about responsibility for
recovery revealed that counselors assigned higher than
neutral responsibility for addiction’s onset and higher than
neutral responsibility for addiction’s recovery (M = 3.57,
SD = 0.73).
Regression models
Tables 3, 4, 5, 6, 7 and 8 present the full results of the
regression models for each of the six objections to theTable 2 Distribution of counselor views of responsibility and
Responsibility for onset
Persons with alcoholism are responsible for the onset of their dependency.
Persons with alcoholism could have avoided their dependence.
Responsibility for recovery
Persons with alcoholism are personally responsible for their recovery.
Persons with alcoholism are personally responsible for creating a solution.
Objection
Paul will be unlikely to comply with taking the medication.
The medication’s side effects (which include nausea, headache, dizziness,
anxiety and a small risk of withdrawal symptoms) are not worth its benefits.
There’s a risk that Paul will use opioids that interfere with the medication
and cause serious side effects.
Naltrexone will treat the symptoms of Paul’s alcoholism, but it will not impro
the underlying causes of his alcohol abuse.
Overcoming alcoholism without the use of medication will strengthen Paul’s
and willpower.
The medication will diminish Paul’s motivation to help himself and participat
the 12-step program.use of naltrexone for a person with alcohol addiction. In
this section, we highlight the predictor variables that are
the most consistent significant predictors of greater
agreement with objections to medication. We also high-
light counselor-characteristic variables that served as sig-
nificant predictors of greater endorsement of objections.
The counselor-characteristic variables (Model 1 in
Tables 3, 4, 5, 6, 7 and 8) largely failed to significantly pre-
dict greater or lesser agreement with the objections to nal-
trexone. In addition, the R2 values reported in Tables 3, 4,
5, 6, 7 and 8 for Model 1 highlight that the variables failed
to explain a large proportion of the variance in this agree-
ment. The only counselor characteristic that was a sig-
nificant predictor of greater agreement with an objection
when views about responsibility were added in Models
2–4 was the counselor treating a higher percentage of
out of pocket clients. This predicted significantly greater
agreement with the objection that naltrexone will treat the
symptoms of alcohol abuse but not its underlying causes
(Table 6), when examined in combination with views of
responsibility for onset (β = 0.26, t(103) = 2.94, p = 0.004),
for recovery (β = 0.27, t(103) = 2.94, p = 0.004), and with
combined views (β = 0.28, t(103) = 3.11, p = 0.002). This
characteristic also predicted stronger agreement with two
other objections (medication’s side effects are not worth
its benefits, and the person will take opioids that inter-
fere), but at the p < 0.05 level rather than our Bonferroni
adjusted cutoff of p < 0.008 (Table 4; Table 5).
In contrast to counselor characteristics that largely
failed to predict strength of agreement with objections, a







2.6% 24.8% 22.2% 35.0% 15.4%
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3.4% 14.5% 23.9% 40.2% 17.9%
1.7% 25.7% 35.9% 25.6% 11.1%
8.5% 37.6% 19.7% 23.9% 10.3%
12.0% 21.4% 22.2% 25.6% 18.8%
ve 2.5% 12.0% 26.5% 46.2% 12.8%
resolve 1.7% 3.4% 18.0% 39.3% 37.6%
e in 6.8% 27.3% 19.7% 36.8% 9.4%
Table 3 Factors predicting objection that persons will not comply with naltrexone
Model 1 Model 2 Model 3 Model 4
Predictor B SE B β B SE B β B SE B β B SE B β
Gender (0 = female; 1 =male) 0.05 0.20 0.02 0.02 0.19 0.01 0.05 0.20 0.02 0.05 0.19 0.02
Age 0.02 0.01 0.18 0.02 0.01 0.19 0.02 0.01 0.18 0.02 0.01 0.18
Type of schooling
PhD −0.46 0.38 −0.13 −0.48 0.36 −0.13 −0.46 0.38 −0.13 −0.46 0.37 −0.13
MD −0.19 0.48 −0.04 −0.39 0.47 −0.08 −0.19 0.49 −0.04 −0.17 0.47 −0.03
Master’s-level −0.13 0.31 −0.04 −0.19 0.30 −0.07 −0.13 0.31 −0.04 −0.16 0.31 −0.06
Bachelor’s-level −0.02 0.24 −0.01 −0.08 0.23 −0.04 −0.02 0.24 −0.01 −0.05 0.23 −0.03
Other education 0.11 0.34 0.03 0.15 0.33 0.05 0.11 0.34 0.03 0.14 0.34 0.05
Years working with substance abuse −0.19* 0.09 −0.21* −0.17 0.09 −0.19 −0.19 0.09 −0.21 −0.17 0.09 −0.20
Percentage privately insured clients 0.00 0.00 −0.03 0.00 0.00 −0.09 0.00 0.00 −0.03 0.00 0.00 −0.07
Percentage publicly insured clients 0.01 0.00 0.19 0.00 0.00 0.10 0.01 0.00 0.19 0.00 0.00 0.14
Percentage out of pocket clients 0.00 0.00 0.14 0.01 0.00 0.16 0.00 0.00 0.14 0.01 0.00 0.16
Personally recovering from addiction (0 = no; 1 = yes) 0.34 0.22 0.16 0.23 0.21 0.10 0.34 0.22 0.16 0.25 0.22 0.11
Responsibility for addiction onset 0.32** 0.10 0.31**
Responsibility for addiction recovery 0.00 0.12 0.00
Combined responsibility 0.27 0.14 0.20
R2 0.16 0.23 0.16 0.19
F F (12, 104) = 1.68 F (13, 103) = 2.44** F (13, 103) = 1.54 F (13, 103) = 1.89*
Notes: for education, high school was reference group; *p ≤ 0.05, **p ≤ .01, ***p ≤ 0.001.
Table 4 Factors predicting objection that naltrexone’s side effects are not worth its benefits
Model 1 Model 2 Model 3 Model 4
Predictor B SE B β B SE B β B SE B β B SE B β
Gender (0 = female; 1 =male) 0.14 0.24 0.06 0.11 0.23 0.04 0.16 0.24 0.07 0.13 0.23 0.06
Age 0.01 0.01 0.12 0.01 0.01 0.13 0.01 0.01 0.12 0.01 0.01 0.12
Type of schooling
PhD 0.04 0.46 0.01 0.03 0.44 0.01 0.05 0.45 0.01 0.04 0.43 0.01
MD 0.06 0.59 0.01 −0.20 0.56 −0.04 0.30 0.58 0.05 0.09 0.55 0.02
Master’s-level −0.25 0.38 −0.07 −0.33 0.36 −0.10 −0.27 0.37 −0.08 −0.33 0.36 −0.10
Bachelor’s-level −0.12 0.29 −0.05 −0.19 0.28 −0.08 −0.13 0.28 −0.05 −0.18 0.27 −0.07
Other education −0.17 0.42 −0.05 −0.11 0.40 −0.03 −0.13 0.41 −0.04 −0.09 0.40 −0.02
Years working with substance abuse −0.15 0.11 −0.15 −0.13 0.11 −0.12 −0.14 0.11 −0.14 −0.13 0.11 −0.12
Percentage privately insured clients 0.00 0.00 0.06 0.00 0.00 −0.01 0.00 0.00 0.02 0.00 0.00 −0.02
Percentage publicly insured clients 0.00 0.00 0.11 0.00 0.00 0.01 0.00 0.00 0.09 0.00 0.00 0.02
Percentage out of pocket clients 0.01 0.00 0.17 0.01* 0.00 0.19* 0.01* 0.00 0.20* 0.01* 0.00 0.21*
Personally recovering from addiction (0 = no; 1 = yes) 0.30 0.26 0.12 0.15 0.26 0.06 0.19 0.26 0.07 0.09 0.26 0.04
Responsibility for addiction onset 0.42*** 0.12 0.34***
Responsibility for addiction recovery 0.33* 0.14 0.23*
Combined Responsibility 0.59*** 0.16 0.37***
R2 0.09 0.18 0.14 0.20
F F (12, 104) = 0.85 F (13, 103) = 1.74 F (13, 103) = 1.25 F(13, 103) = 1.93*
Notes: for education, high school was reference group; *p ≤ 0.05, **p ≤ .01, ***p ≤ 0.001.
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Table 5 Factors predicting objection that persons will take opioids that interfere with naltrexone/are associated with
serious side effects
Model 1 Model 2 Model 3 Model 4
Predictor B SE B β B SE B β B SE B β B SE B β
Gender (0 = female; 1 =male) 0.12 0.26 0.04 0.10 0.26 0.04 0.14 0.26 0.05 0.12 0.26 0.04
Age −0.01 0.01 −0.07 −0.01 0.01 −0.06 −0.01 0.01 −0.07 −0.01 0.01 −0.07
Type of schooling
PhD 0.76 0.50 0.16 0.75 0.50 0.16 0.76 0.50 0.17 0.76 0.49 0.16
MD 1.11 0.64 0.17 0.94 0.64 0.15 1.28 0.65 0.20 1.13 0.63 0.18
Master’s-level 0.67 0.42 0.18 0.62 0.41 0.16 0.66 0.41 0.17 0.62 0.41 0.16
Bachelor’s-level 0.45 0.32 0.17 0.40 0.31 0.15 0.44 0.31 0.16 0.41 0.31 0.15
Other education 0.54 0.46 0.14 0.58 0.45 0.15 0.57 0.45 0.14 0.60 0.45 0.15
Years working with substance abuse 0.00 0.12 0.00 0.01 0.12 0.01 0.00 0.12 0.00 0.01 0.12 0.01
Percentage privately insured clients 0.00 0.00 0.04 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 −0.01
Percentage publicly insured clients 0.01 0.00 0.12 0.00 0.00 0.06 0.00 0.00 0.10 0.00 0.00 0.06
Percentage out of pocket clients 0.01* 0.00 0.20* 0.01* 0.00 0.21* 0.01* 0.00 0.22* 0.01* 0.00 0.23*
Personally recovering from addiction (0 = no; 1 = yes) 0.09 0.29 0.03 0.00 0.29 0.00 0.02 0.29 0.01 −0.04 0.29 −0.02
Responsibility for addiction onset 0.28 0.14 0.20
Responsibility for addiction recovery 0.23 0.15 0.15
Combined responsibility 0.40* 0.18 0.22*
R2 0.12 0.17 0.14 0.16
F F (12, 104) = 1.17 F(13, 103) = 1.40 F (13, 103) = 1.27 F(13, 103) = 1.49
Notes: for education, high school was reference group; *p ≤ 0.05, **p ≤ .01, ***p ≤ 0.001.
Table 6 Factors predicting objection that naltrexone will treat the symptoms of alcohol abuse, but not its underlying
causes
Model 1 Model 2 Model 3 Model 4
Predictor B SE B β B SE B β B SE B Β B SE B β
Gender (0 = female; 1 =male) −0.38* 0.18 −0.19* −0.40* 0.18 −0.20* −0.37* 0.18 −0.19* −0.38* 0.18 −0.19*
Age −0.01 0.01 −0.11 −0.01 0.01 −0.10 −0.01 0.01 −0.11 −0.01 0.01 −0.10
Type of schooling
PhD 0.66 0.35 0.19 0.65 0.34 0.19 0.66 0.35 0.20 0.66 0.34 0.19
MD 0.37 0.45 0.08 0.20 0.44 0.04 0.52 0.45 0.11 0.39 0.43 0.08
Master’s-level 0.33 0.29 0.12 0.27 0.28 0.10 0.31 0.29 0.11 0.28 0.28 0.10
Bachelor’s-level 0.28 0.22 0.14 0.23 0.22 0.12 0.27 0.22 0.13 0.24 0.21 0.12
Other education 0.59 0.32 0.20 0.63* 0.31 0.22* 0.62 0.32 0.21 0.65* 0.31 0.22*
Years working with substance abuse 0.02 0.09 0.02 0.03 0.08 0.04 0.02 0.09 0.02 0.03 0.08 0.04
Percentage privately insured clients 0.01* 0.00 0.25* 0.01* 0.00 0.19* 0.01 0.00 0.22 0.01 0.00 0.18
Percentage publicly insured clients 0.00 0.00 −0.12 −0.01* 0.00 −0.20* 0.00 0.00 −0.14 −0.01* 0.00 −0.20*
Percentage out of pocket clients 0.01* 0.00 0.25* 0.01** 0.00 0.26** 0.01** 0.00 0.27** 0.01** 0.00 0.28**
Personally recovering from addiction (0 = no; 1 = yes) −0.05 0.20 −0.02 −0.14 0.20 −0.07 −0.12 0.20 −0.06 −0.18 0.20 −0.08
Responsibility for addiction onset 0.27** 0.10 0.27**
Responsibility for addiction recovery 0.21* 0.11 0.19*
Combined responsibility 0.38** 0.13 0.29**
R2 0.19 0.25 0.22 0.26
F F (12, 104) = 2.05* F(13, 103) = 2.59** F(13, 103) = 2.25* F(13, 103) = 2.74**
Notes: for education, high school was reference group; *p ≤ 0.05 ** p ≤ .01, *** p ≤ 0.001.
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Table 7 Factors predicting objection that overcoming alcoholism without medication strengthens a person’s resolve/willpower
Model 1 Model 2 Model 3 Model 4
Predictor B SE B β B SE B β B SE B β B SE B β
Gender (0 = female; 1 =male) −0.26 0.19 −0.13 −0.26 0.19 −0.14 −0.24 0.19 −0.12 −0.26 0.19 −0.13
Age 0.01 0.01 0.11 0.01 0.01 0.12 0.01 0.01 0.11 0.01 0.01 0.12
Type of schooling
PhD 0.12 0.37 0.04 0.12 0.37 0.04 0.13 0.36 0.04 0.12 0.36 0.04
MD −0.32 0.47 −0.07 −0.35 0.47 −0.08 −0.09 0.46 −0.02 −0.30 0.46 −0.07
Master’s-level 0.00 0.30 0.00 −0.01 0.31 −0.01 −0.02 0.29 −0.01 −0.04 0.30 −0.01
Bachelor’s-level 0.10 0.23 0.05 0.09 0.23 0.05 0.09 0.22 0.05 0.07 0.23 0.04
Other education −0.01 0.33 −0.01 −0.01 0.33 0.00 0.02 0.32 0.01 0.02 0.33 0.01
Years working with substance abuse −0.01 0.09 −0.02 −0.01 0.09 −0.01 −0.01 0.09 −0.01 0.00 0.09 0.00
Percentage privately insured clients 0.00 0.00 −0.03 0.00 0.00 −0.04 0.00 0.00 −0.07 0.00 0.00 −0.07
Percentage publicly insured clients 0.00 0.00 0.11 0.00 0.00 0.09 0.00 0.00 0.08 0.00 0.00 0.05
Percentage out of pocket clients 0.00 0.00 −0.04 0.00 0.00 −0.03 0.00 0.00 0.00 0.00 0.00 −0.01
Personally recovering from addiction (0 = no; 1 = yes) −0.13 0.21 −0.07 −0.15 0.21 −0.07 −0.23 0.21 −0.12 −0.22 0.21 −0.11
Responsibility for addiction onset 0.05 0.10 0.05
Responsibility for addiction recovery 0.30** 0.11 0.28**
Combined responsibility 0.26 0.13 0.21
R2 0.06 0.07 0.13 0.10
F F(12, 104) = 0.62 F(13, 103) = 0.58 F(13, 103) = 1.21 F(13, 103) = 0.88
Notes: for education, high school was reference group; *p ≤ 0.05, **p ≤ .01, ***p ≤ 0.001.
Table 8 Factors predicting objection that the medication will diminish a person’s motivation to help himself/participate
in the 12-step program
Model 1 Model 2 Model 3 Model 4
Predictor B SE B β B SE B β B SE B β B SE B β
Gender (0 = female; 1 =male) −0.10 0.24 −0.04 −0.13 0.23 −0.05 −0.09 0.24 −0.04 −0.10 0.23 −0.04
Age −0.01 0.01 −0.06 −0.01 0.01 −0.05 −0.01 0.01 −0.06 −0.01 0.01 −0.06
Type of schooling
PhD 0.22 0.45 0.05 0.21 0.44 0.05 0.22 0.45 0.06 0.22 0.44 0.05
MD −0.02 0.57 0.00 −0.24 0.56 −0.04 0.06 0.58 0.01 0.00 0.56 0.00
Master’s-level −0.29 0.37 −0.09 −0.36 0.36 −0.11 −0.30 0.37 −0.09 −0.34 0.37 −0.10
Bachelor’s-level −0.13 0.28 −0.05 −0.19 0.28 −0.08 −0.13 0.28 −0.06 −0.17 0.28 −0.07
Other education −0.24 0.41 −0.07 −0.19 0.40 −0.05 −0.22 0.41 −0.06 −0.19 0.40 −0.05
Years working with substance abuse −0.02 0.11 −0.02 0.00 0.11 0.00 −0.01 0.11 −0.01 0.00 0.11 0.00
Percentage privately insured clients 0.01 0.00 0.16 0.00 0.00 0.10 0.01 0.00 0.15 0.00 0.00 0.11
Percentage publicly insured clients 0.00 0.00 0.04 0.00 0.00 −0.05 0.00 0.00 0.03 0.00 0.00 −0.03
Percentage out of pocket clients 0.00 0.00 0.10 0.00 0.00 0.12 0.00 0.00 0.11 0.00 0.00 0.13
Personally recovering from addiction (0 = no; 1 = yes) −0.07 0.26 −0.02 −0.19 0.25 −0.08 −0.11 0.26 −0.04 −0.20 0.26 −0.08
Responsibility for addiction onset 0.35** 0.12 0.29**
Responsibility for addiction recovery 0.11 0.14 0.08
Combined responsibility 0.37* 0.16 0.24*
R2 0.07 0.13 0.07 0.11
F F (12, 104) = 0.62 F(13, 103) = 1.21 F(13, 103) = 0.62 F(13, 103) = 1.00
Notes: for education, high school was reference group; *p ≤ 0.05, **p ≤ .01, ***p ≤ 0.001.
Johnson et al. Substance Abuse Treatment, Prevention, and Policy  (2015) 10:10 Page 9 of 13
Johnson et al. Substance Abuse Treatment, Prevention, and Policy  (2015) 10:10 Page 10 of 13predictive relationships that were both more significant and
more consistent across objections to the use of naltrexone
for alcohol addiction. More specifically, a counselor assign-
ing higher responsibility to a person for the onset of
their addiction (Model 2) significantly predicted stronger
agreement with 1) the idea that persons are unlikely to
comply with naltrexone (β = 0.31, t(103) = 3.13, p = 0.002)
(Table 3), 2) naltrexone’s side effects are not worth its
benefits (B = 0.34, t(103) = 3.39, p = 0.001). (Table 4),
3) naltrexone treats alcohol abuse’s symptoms but not
its underlying cause (β = 0.27, t(103) = 2.75, p = 0.007)
(Table 6), and 4) medication will diminish a person’s
motivation to help themselves (β = 0.29, t(103) = 2.80, p =
0.006) (Table 8). Views about a person’s responsibility for
recovery from addiction (Model 3) were less predictive,
only significantly predicting stronger agreement with the
idea that overcoming alcoholism without medication
strengthens resolve and willpower (β = 0.28, t(103) = 2.79,
p = 0.006) (Table 7). The combined measure of a person’s
responsibility for onset and for recovery predicted signifi-
cantly stronger agreement with two objections: 1) naltrex-
one’s side effects are not worth its benefits (β = 0.37,
t(103) = 3.69, p < 0.001) (Table 4) and 2) naltrexone treats
alcohol abuse’s symptoms but not its underlying cause
(β = 0.29, t(103) = 3.02, p = 0.003) (Table 6). However, this
effect seems to be driven largely by views of responsibility
for onset rather than views of responsibility for recovery.
Discussion
Results from our vignette-based study of addiction coun-
selors indicate that a counselor’s assignment of greater
responsibility for alcohol addiction is associated with
stronger agreement with various objections to the use
of a medication—naltrexone—for alcohol addiction treat-
ment. In particular, counselors who assign a person
greater degrees of responsibility for addiction’s onset dis-
play stronger agreement to four of the six objections to
naltrexone we investigated. These objections included both
issues related to naltrexone’s efficacy, such as the medica-
tion’s side effects not being worth its benefits, as well as
concerns that medication might diminish a person’s motiv-
ation to help themselves. While holding a person more
responsible for the onset of addiction was associated with
several objections, beliefs about a person’s responsibility
for recovery were less predictive. The study, one of
the first to link the literature on counselor beliefs about
responsibility for addiction with the literature on counselor
attitudes towards naltrexone, thus illustrates the presence
of a link between these two types of counselor attitudes.
In analyzing these findings, we focus on three sets of
questions. First, what do the particular objections to the
use of medication that counselors endorse reveal about
the relationship between responsibility-focused views of
addiction and negative evaluations of naltrexone? Second,why does the counselor’s percentage of out-of-pocket cli-
ents also matter in their skepticism towards medication?
Third, how do the findings relate to the broader literature
on the limited uptake of the “brain disease” model of ad-
diction among clinical practitioners?Views of responsibility and clinical evidence
Interestingly, many of the objections that counselors
more strongly endorse could be characterized as clinical
in nature rather than deep-seated opposition to the idea
of using any medication to treat addiction. These in-
clude worries about compliance and side effects. Each of
these objections has some empirical support in the clin-
ical literature on naltrexone, but presumably, counselors
with different views of responsibility should assess this
clinical evidence in similar ways. The fact that coun-
selors in our sample with different views of responsibility
for addiction assessed the evidence in significantly differ-
ent ways presents an interesting finding about the inter-
action between attributions of addiction responsibility
and the weighing of evidence.
The present study only examined that counselors’
negative attitudes towards naltrexone are linked to hold-
ing persons more individually responsible for addiction’s
onset. Future research should investigate mechanisms
by which these views become linked. One possible mech-
anism that future research should investigate include:
responsibility-oriented treatment professionals may attune
themselves more to articles they read on the unpleasant
side effects of a medication, data on lack of compliance
among clients, and information on negative drug-drug in-
teractions, than counselors who are less responsibility-
oriented and more inclined towards positive evaluations
of medication.Client insurance status and skepticism towards
medication
Second, the present study found no significant predictive
roles for certain counselor characteristics that other re-
search finds either contribute to views of responsibility
or contribute to reluctance to prescribe naltrexone: for
example, that counselors who are personally recovering
from addiction hold persons less responsible for the
condition [4] or that counselors who treat a larger per-
centage of Medicaid or uninsured clients display lower
support for medication [23]. Instead, we found that a
counselor treating a higher percentage of clients who
pay out of pocket for treatment significantly predicted
greater agreement with the objection that the medica-
tion may treat the symptoms of alcohol abuse but not its
underlying cause. What might be the link between treat-
ing more out-of-pocket clients and exhibiting greater
skepticism towards medication?
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for several reasons: they may lack insurance or have in-
surance but do not want addiction treatment to appear
in their billing records. However, clients may also pay
out of pocket if they seek care at one of the estimated
50-60% of alcohol and substance addiction centers that
do not accept any form of insurance [29]. Indeed, past
research suggests that treatment programs may be split be-
tween ones that adopt an abstinence-only philosophy that
eschews medication and ones that promote medication-
assisted treatment [30]. Though further research is needed,
it is possible that these organizations that deliberately do
not accept insurance have chosen to opt for a highly
responsibility-focused view of addiction that rejects both
medical insurance and medication. Future work should
explore this possibility by collecting data on the reim-
bursement policies of the treatment centers where coun-
selors work.
The gap between research and practice
Third, this study adds to a growing body of evidence show-
ing that the “chronic relapsing brain disease”model of addic-
tion, though promoted by research leaders in the addiction
community [31], has failed to fully penetrate clinical practice.
This is in spite of support for medication-assisted treat-
ment among many addiction scientists and clients [32].
The present study showed that counselors who hold
responsibility-focused views of addiction view one
achievement of the brain disease model of addiction—
naltrexone—more negatively than counselors with less
responsibility-focused views. Past qualitative research has
shown that some practicing counselors report avoiding
conveying the brain disease model of addiction to clients
out of fear that clients will fail to take “personal responsi-
bility for what’s happening to them” [33]. Supplementing
these interview-based studies are accounts from within
addiction treatment centers that illustrate the centers’
focus on instilling ideas of responsibility into clients and
de-emphasis on medications like naltrexone as a part of
treatment [34]. The present study complements these
qualitative accounts by providing quantitative evidence of
a link between two sets of attitudes that might inhibit
uptake of evidence-based medication.
Limitations
The current study has several limitations. First, although
there were significant correlations between provider’s
views about responsibility and attitudes towards addiction,
our design neither isolated causality nor confirmed direc-
tionality. We did not inquire about negative and positive
past experiences with naltrexone, but future research
should more closely analyze whether views of greater re-
sponsibility for addiction tend to precede and possibly
cause more negative evaluations of naltrexone, or whethermore negative clinical experiences with naltrexone may
result in believing that persons ought to be more respon-
sible for addiction. In addition, these studies should in-
clude both objections to naltrexone and reasons for the
use of naltrexone. Second, the use of only a single case
limited our understanding of subtleties in counselor atti-
tudes towards naltrexone. There may be some clients or
scenarios where providers have greater or lesser confi-
dence in pharmacologic assistance in overcoming addic-
tion. This study examined general provider attitudes
towards naltrexone, but more detailed instruments could
better illuminate nuances in counselor views.
Third, we did not assess the organizational context in
which our respondents worked, which past research has
shown can influence views about medication [35] and
which may also influence views about responsibility for
addiction. For example, respondents from a hospital sys-
tem, working with medically oriented colleagues, may
have endorsed fewer concerns with naltrexone simply due
to greater familiarity with the medication. In contrast,
counselors in 12-step oriented institutions may have min-
imal experience with naltrexone and thus are uncomfort-
able with potential side effects and interactions. More
research on the effects of organizational context on both
understanding of naltrexone and views of addiction re-
sponsibility is needed. Fourth, while there was some diver-
sity of training in our cohort, it was largely composed of
persons with bachelor’s and master’s degrees working at
addiction treatment facilities as counselors. This stemmed
from our choice to recruit a sample that reflected the var-
iety of backgrounds in the addiction treatment workforce.
In addition, we did not measure the caseload mix that the
counselor treats (e.g. only alcohol addiction; a mix of alco-
hol addiction and drug dependence), which may influence
the counselor’s knowledge about and attitudes towards nal-
trexone. Future research could explore whether the findings
hold true for physician-only samples and for counselors
with a variety of caseloads.
Fifth, our desire for a diverse participant pool led to
the use of an online survey. Online surveys run a small
risk that persons might misrepresent their professional
credentials. However, the consent form reiterated that
the study was only intended for trained addiction treat-
ment professionals, hopefully minimizing this possibility.
Sixth, although Qualtrics Panels recruits from a large
sample of potential respondents, there may be biases in
who opts in to the panel in general and then to specific
surveys. Future research should confirm our findings
with efforts to recruit a random, representative sample
of the U.S. addiction treatment workforce.
Conclusion
The present study finds a link between a counselor assign-
ing a higher degree of individual responsibility to a person
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jections to the use of naltrexone. Future research should
investigate factors such as which negative evaluations
most strongly predict a reluctance to prescribe naltrexone,
how different addiction treatment organizations socialize
counselors to adopt certain attitudes about responsibility
for addiction, and how positive and negative experiences
with naltrexone shape these views. Future research should
also extend these investigations to the injectable form of
naltrexone and other anti-addiction medications. These
studies can help inform interventions that address low up-
take of medication-assisted treatment among the addic-
tion treatment workforce.
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